In the metabolic microenvironment, simvastatin has been shown to induce metabolic reprogramming in a mouse model of head and neck squamous cell carcinoma (HNSCC) by reducing the production of lactic acid and cancer sensitivity to monocarboxylate transporter 1 (MCT1) inhibitor, thereby inhibiting HNSCC [125]. Here, SLC16A1 is linked to head and neck squamous cell carcinoma.